Representative Lisa C. McClain (R-Michigan) recently bought shares of Pfizer Inc. NYSE: PFE. In a filing disclosed on August 13th, the Representative disclosed that they had bought between $1,001 and $15,000 in Pfizer stock on July 16th. The trade occurred in the Representative's "CHARLES SCHWAB BROKERAGE ACCOUNT 924" account.
Representative Lisa C. McClain also recently made the following trade(s):
- Sold $1,001 - $15,000 in shares of Autoliv NYSE: ALV on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Amazon.com NASDAQ: AMZN on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Applied Materials NASDAQ: AMAT on 8/4/2025.
- Sold $1,001 - $15,000 in shares of Arthur J. Gallagher & Co. NYSE: AJG on 8/4/2025.
- Sold $1,001 - $15,000 in shares of SAP NYSE: SAP on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of XPO NYSE: XPO on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Lithia Motors NYSE: LAD on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Sanofi NASDAQ: SNY on 7/22/2025.
- Sold $1,001 - $15,000 in shares of Waters NYSE: WAT on 7/22/2025.
- Purchased $1,001 - $15,000 in shares of Group 1 Automotive NYSE: GPI on 7/22/2025.
Pfizer Trading Up 0.2%
Shares of NYSE PFE traded up $0.05 during midday trading on Friday, hitting $25.16. The stock had a trading volume of 31,819,451 shares, compared to its average volume of 45,666,590. The company has a market capitalization of $143.05 billion, a price-to-earnings ratio of 13.38, a PEG ratio of 0.90 and a beta of 0.52. Pfizer Inc. has a 1-year low of $20.92 and a 1-year high of $30.43. The company has a quick ratio of 0.85, a current ratio of 1.16 and a debt-to-equity ratio of 0.65. The company has a fifty day moving average price of $24.56 and a 200 day moving average price of $24.46.
Pfizer (NYSE:PFE - Get Free Report) last released its quarterly earnings results on Tuesday, August 5th. The biopharmaceutical company reported $0.78 EPS for the quarter, topping the consensus estimate of $0.58 by $0.20. Pfizer had a return on equity of 21.42% and a net margin of 16.84%. The firm had revenue of $14.65 billion for the quarter, compared to analyst estimates of $13.43 billion. During the same period in the previous year, the company posted $0.60 EPS. Pfizer's revenue for the quarter was up 10.3% on a year-over-year basis. On average, analysts predict that Pfizer Inc. will post 2.95 earnings per share for the current year.
Pfizer Announces Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, September 2nd. Stockholders of record on Friday, July 25th will be paid a $0.43 dividend. This represents a $1.72 annualized dividend and a dividend yield of 6.8%. The ex-dividend date of this dividend is Friday, July 25th. Pfizer's payout ratio is currently 91.49%.
Institutional Inflows and Outflows
A number of institutional investors have recently added to or reduced their stakes in PFE. Clarity Asset Management Inc. bought a new position in Pfizer during the 4th quarter worth $27,000. Gould Capital LLC grew its stake in Pfizer by 97.2% during the 4th quarter. Gould Capital LLC now owns 1,000 shares of the biopharmaceutical company's stock worth $27,000 after buying an additional 493 shares during the last quarter. GKV Capital Management Co. Inc. bought a new position in shares of Pfizer in the first quarter worth $27,000. Curio Wealth LLC grew its stake in shares of Pfizer by 36,600.0% in the second quarter. Curio Wealth LLC now owns 1,101 shares of the biopharmaceutical company's stock worth $27,000 after purchasing an additional 1,098 shares in the last quarter. Finally, North Capital Inc. bought a new position in shares of Pfizer in the first quarter worth $28,000. 68.36% of the stock is currently owned by institutional investors.
Wall Street Analysts Forecast Growth
PFE has been the topic of a number of recent analyst reports. Bank of America upped their target price on Pfizer from $27.00 to $28.00 and gave the company a "neutral" rating in a research report on Wednesday, August 6th. Wolfe Research upped their target price on Pfizer from $22.00 to $23.00 and gave the company an "underperform" rating in a research report on Wednesday, April 30th. Berenberg Bank cut their target price on Pfizer from $28.00 to $25.00 and set a "hold" rating on the stock in a research report on Thursday, May 29th. HSBC cut their target price on Pfizer from $27.00 to $26.00 and set a "buy" rating on the stock in a research report on Monday, May 19th. Finally, Leerink Partners cut their target price on Pfizer from $28.00 to $26.00 and set a "market perform" rating on the stock in a research report on Wednesday, April 30th. One equities research analyst has rated the stock with a sell rating, eleven have assigned a hold rating, five have issued a buy rating and two have assigned a strong buy rating to the company. According to data from MarketBeat.com, the stock currently has an average rating of "Hold" and an average target price of $28.12.
Get Our Latest Stock Report on Pfizer
About Representative McClain
Lisa McClain (Republican Party) is a member of the U.S. House, representing Michigan's 9th Congressional District. She assumed office on January 3, 2023. Her current term ends on January 3, 2027.
McClain (Republican Party) is running for re-election to the U.S. House to represent Michigan's 9th Congressional District. She declared candidacy for the 2026 election.
Lisa McClain lives in Romeo, Michigan. McClain earned a bachelor's degree in business administration from Northwood University. Her career experience includes founding and working as the president of North End Support Team.
About Pfizer
(
Get Free Report)
Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.
Featured Articles
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Pfizer, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Pfizer wasn't on the list.
While Pfizer currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
MarketBeat All Access